We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the prognostic role of PNI in 147 ES-SCLC patients treated with platinum-based combination regimen between 2011 and 2018. Kaplan-Meier survival analyses and Cox proportional hazard models were used to examine the effects of basal PNI on overall survival (OS). The median age of the patients was 61 (range 38-81). The cutoff value for PNI was determined for whole group and patients were dichotomized into high (≥49.17) and low (<49.17). Seventy-eight (53.1%) patients had low PNI score and 69 (46.9%) patients had high PNI score. Patients with the high PNI score had better OS than those with low PNI (13 versus 12 months, respectively, and P = 0.03). The relationship between PNI score and OS was more prominent in patients over 65 years of age (13 versus 10 months, respectively, and P = 0.03). Progression-free survival of patients with complete response to first-line treatment was statistically significantly better than the other patients (8 versus 7 months, respectively, and P = 0.02). Similarly, OS was statistically significantly better than the other patients (15 versus 8 months, respectively, and P = 0.001). The results of our study show that PNI score is useful in evaluating the OS of patients with ES-SCLC. PNI is a cost-effective prognostic marker and should therefore be included in routine clinical practice.

中文翻译：

---

预后营养指数对广泛期小细胞肺癌的预后价值。

我们的目的是评估治疗前预后营养指数 (PNI) 对接受一线化疗的广泛期小细胞肺癌 (ES-SCLC) 患者的预后和预测意义。我们设计本研究是为了评估 PNI 在 2011 年至 2018 年间接受铂类联合方案治疗的 147 名 ES-SCLC 患者中的预后作用。Kaplan-Meier 生存分析和 Cox 比例风险模型用于检查基础 PNI 对总体的影响生存期（OS）。患者的中位年龄为 61 岁（范围 38-81 岁）。确定整个组的 PNI 截止值，并将患者分为高（≥49.17）和低（<49.17）。78 名患者 (53.1%) 的 PNI 评分较低，69 名患者 (46.9%) 的 PNI 评分较高。PNI 评分高的患者比 PNI 评分低的患者有更好的 OS（分别为 13 个月和 12 个月，P = 0.03）。PNI 评分与 OS 之间的关系在 65 岁以上的患者中更为明显（分别为 13 个月和 10 个月，P = 0.03）。对一线治疗完全缓解的患者的无进展生存期在统计学上显着优于其他患者（分别为 8 个月和 7 个月，P = 0.02）。同样，OS 在统计学上显着优于其他患者（分别为 15 个月和 8 个月，P = 0.001）。我们的研究结果表明，PNI 评分有助于评估 ES-SCLC 患者的 OS。PNI 是一种具有成本效益的预后标志物，因此应纳入常规临床实践。